Naoum Joseph J, Arbid Elias J
The Methodist Hospital, Houston, Texas, USA.
Methodist Debakey Cardiovasc J. 2013 Apr;9(2):103-7. doi: 10.14797/mdcj-9-2-103.
Critical limb ischemia (CLI) results from inadequate blood flow to supply and sustain the metabolic needs of resting muscle and tissue. Infragenicular atherosclerosis is the most common cause of CLI, and it is more likely to develop when multilevel or diffuse arterial disease coincides with compromised run-off to the foot. Reports of good technical and clinical outcomes have advanced the endovascular treatment options, which have gained a growing acceptance as the primary therapeutic strategy for CLI, especially in patients with significant risk factors for open surgical bypass. In fact, endovascular recanalization of below-the-knee arteries has proven to be feasible and safe, reduce the need for amputation, and improve wound healing. The distribution of various vascular territories or angiosomes in the foot has been recognized, and it appears advantageous to revascularize the artery supplying the territory directly associated with tissue loss. In addition, the targeted application and local delivery of drugs using drug-coated balloons (DCB) during angioplasty has the potential to improve patency rates compared to balloon angioplasty alone.
严重肢体缺血(CLI)是由于血流不足,无法供应和维持静息肌肉和组织的代谢需求所致。膝下动脉粥样硬化是CLI最常见的病因,当多节段或弥漫性动脉疾病与足部血流灌注受损同时存在时,更易发生CLI。关于良好技术和临床疗效的报道推动了血管内治疗方案的发展,血管内治疗作为CLI的主要治疗策略已越来越被接受,尤其是对于有开放手术旁路显著危险因素的患者。事实上,膝下动脉的血管内再通已被证明是可行且安全的,可减少截肢需求并促进伤口愈合。足部不同血管区域或血管体的分布已得到确认,直接对与组织缺损直接相关区域供血的动脉进行血运重建似乎具有优势。此外,与单纯球囊血管成形术相比,在血管成形术中使用药物涂层球囊(DCB)进行靶向给药和局部药物递送有可能提高通畅率。